The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive (pneumococcal polysaccharide conjugate vaccine [21-valent]) intended to ...

Drug major Merck & Co. (MRK) announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use or ...

Keep up-to-date with everything that happens in your world. We promise to never spam you. You can opt-out at any time. Please refer to our Privacy Policy for ...

Just one in four (25%) people at high risk of pneumococcal disease, an infection that causes pneumonia—children younger than 2, adults older than 64, and those with certain chronic health ...

Two pneumonia-causing bacteria have been at especially high ... with one of the lowest rates being the pneumococcal vaccine that is recommended for children under 5, according to a September ...

“We start vaccinating against that early in life, and that works very well. But because the pneumococcal bacteria has so many different strains, we can’t protect against every strain with the ...

Australia is battling a disease outbreak that has seen some of the country's most vulnerable residents plagued by a life-threatening bacterial infection. Thousands of children aged under two have ...

As pneumococcus is an important cause of secondary bacterial pneumonia following viral respiratory infection (41, 42), a severe viral respiratory disease season could be grounds for vaccination.

Colombian and Panama were also chosen by GSK as staging grounds for trials of the vaccine against the pneumococcal bacteria. Likewise, Marchese, explained the modus operandi: “Once a picked ...